Abstract Purpose: Telomeres consisting of a repeating nucleotide sequence (TTAGGG)n are shortened in normal somatic cells. Telomerase is an enzyme that elongates the telomere sequence and is detected in most human cancers and usually not in normal somatic cells. Little is known about telomerase activity in bone and soft tissue tumors. The aim of this study was to investigate the relationship between telomerase activity and clinical factors in bone and soft tissue tumors. Methods: Telomerase activity was measured using the modified telomeric repeat amplification protocol (TRAP) assay in 115 bone and soft tissue tumors obtained through open biopsy or resection. Results: Telomerase activity was detected in 10% of benign tumors and 44% of malignant tumors (p<0.001). A higher incidence of telomerase activity was detected in high-grade tumors than in lowgrade tumors (p=0.002). The cumulative metastasis-free and overall survival in telomerase-positive patients was significantly worse than in telomerase-negative patients (p=0.045 and p=0.048). Conclusion: Our study suggests that telomerase activity is associated with tumor aggressiveness and may be a useful parameter to predict the prognosis of patients with malignant bone and soft tissue tumors.
Introduction
Chromosome ends are composed of specialized nucleoprotein structures called telomeres. Telomeres consist of a repeating nucleotide sequence (TTAGGG)n and are essential for stable chromosome maintenance (Blackburn 1991) . They are shortened at each cell division in normal somatic cells due to the end replication problem (Harley 1991) . The loss of telomeres is considered to result in cell senescence (Levy et al. 1992) . In neoplasms, telomere maintenance is required for their immortality (Shay and Wright 1996) . Telomerase is an enzyme that elongates telomere sequences and is detected in most human cancers and usually not detected in normal somatic cells. The incidence of positive telomerase activity is high in about 81-100% of carcinomas (Meeker and Coffey 1997; Shay and Bacchetti 1997) . However, it is detected in a comparatively low percentage of bone and soft tissue tumors (17-81%) (Aue et al. 1998; Yoo and Robinson 2000; Yan et al. 1999; Schneider-Stock et al. 2000 , Aogi et al. 2000 Sangiorgi et al. 2001; Tomoda et al. 2002) . Although telomerase activity has been shown to be a prognostic factor of carcinomas, there are few reports on the prognosis with bone and soft tissue tumors. In this study, we investigated the relationship between telomerase activity and the clinical factors in bone and soft tissue tumors. with abundant stock samples and from which DNA could be extracted were selected for analysis. Fifty-two tumors occurred in 51 female patients and 63 tumors occurred in 61 male patients. The patients' median age was 39.7 (range: 10-80) years (Table 1) . Eighty-seven tumors were located in the extremities and 28 in the trunk. The 115 tumors were composed of 13 benign bone tumors, 17 benign soft tissue tumors, 35 malignant bone tumors, and 50 malignant soft tissue tumors. The malignant tumors were divided according to the tumor grade evaluated by Enneking's surgical grading system (Enneking 1986 Table 2 .
Materials and methods

Tumor samples
After surgical excision of the tumors, samples were immediately frozen and preserved at )80°C. The Ethics Committee of Okayama University approved the usage of tumor samples for analyses.
Telomerase activity assay
Telomerase activity was measured by the modified telomeric repeat amplification protocol (TRAP) assay (TeloChaser Ò TOYOBO, Osaka, Japan). The frozen tissue specimens were pulverized and washed with cold phosphate-buffered saline in microtubes. They were homogenized with 150 ll lysis solution and incubated on ice for 30 min. They were then centrifuged at 15,000 r.p.m. at 4°C for 30 min. The supernatant was immediately frozen at )80°C and stored until use. The protein content in each lysate was measured and adjusted to 5 lg/20 ll with the lysis solution. The lysate was mixed with 20 ll extension mix (8 ll distilled water, 8 ll 5· extension buffer, 4 ll primer mix). Lysis solution with no sample was used as a negative control, and the HeLa cells were used as a positive control. After a telomerase-mediated reaction for 60 min at 37°C, they were denatured for 150 s at 95°C then amplified for 30 cycles at 95°C for 30 s, at 68°C for 30 s, and at 72°C for 45 s. The polymerase chain reaction products were loaded onto a 10 cm electrophoresis apparatus using 10% polyacrylamide gel and were run at 100 volts. After electrophoresis, the gel was soaked in diluted SYBR Green I for 20 min. The samples were judged positive for telomerase activity if the ladder of every sixth base was observed under ultraviolet radiation. If it was not observed regularly, the samples were judged false-positive for telomerase activity (Fig. 1) .
Statistical analysis
First, the effect of preoperative therapy on telomerase activity was analyzed in 71 high-grade tumors in Groups II and III by chi-square test. To exclude the influence of preoperative therapy on telomerase activity, further analyses were performed in Groups I and II. The relationship between telomerase activity and the clinical factors was analyzed by chi-square test: age (over or Fig. 1 The expression of telomerase activity using the telomeric repeat amplification protocol (TRAP) assay The ladders in Lanes 2, 5, and 7 were clearly expressed; however, those in Lanes 1, 3, 4, and 6 were not clear. The ladders in Lanes 2, 5, and 7 were judged positive, and those in Lanes 1, 3, 4, and 6 were false-positive. Metastasis-free and overall survival were calculated by the Kaplan-Meier method, and the significance of the survival curves was evaluated by log-rank test. These were analyzed only in the primary high-grade tumors. The starting point of follow-up was defined as the day of the first surgical treatment aimed at complete tumor removal. The median follow-up in the primary highgrade tumors was 66 (range: 12-211) months. A p value <0.05 was considered statistically significant.
Results
Twenty-four high-grade tumors underwent preoperative therapy, and 47 high-grade tumors did not. Telomerase activity was detected in 55% of the tumors without preoperative therapy (Group II) and in 29% of the highgrade tumors with preoperative therapy (Group III). Telomerase activity in the high-grade tumors without preoperative therapy (Group II) was significantly higher than with preoperative therapy (Group III) (p=0.037) ( Table 3) .
Further analyses were limited in Groups I and II in order to exclude the effect of anticancer agents or radiation on the tumor cells. Telomerase activity was detected in 10% of benign tumors (3/30) and in 44% of malignant tumors (27/61) ( Table 3) . Telomerase activity in malignant tumors was significantly higher than in benign tumors (p<0.001) (Fig. 2) .
In benign tumors (Group I), the three telomerasepositive tumors were two giant cell tumors (GCTs) (2/4 GCTs) and one enchondroma (1/2 enchondromas). None of the benign soft tissue tumors showed telomerase activity.
In the malignant tumors (Group II), there were no significant differences regarding telomerase activity among age, gender, and location (Table 3) . Telomerase activity was detected in 43% of bone tumors (10/23) and 45% of soft tissue tumors (17/38). It was detected in 46% of primary malignant tumors (26/56) and in 20% of recurrent tumors (1/5). There were no significant differences regarding telomerase activity between tumor type (bone or soft) and local recurrence (primary or recurrent). Among the five patients with recurrent tumors, one with a telomerase-positive tumor had a recurrence 5 months after definitive excision, and four patients with telomerase-negative tumors had local Fig. 2 Telomerase activity and bone and soft tissue tumors (benign or malignant, low or high grade). Telomerase activity in malignant tumors was significantly higher than in benign tumors, and telomerase activity in high-grade tumors was significantly higher than in low-grade tumors recurrence at 10, 21, 23, and 58 months. There was no recurrence during the course of our follow-up after collection of tumor samples. Telomerase activity was detected in eight of 14 osteosarcomas, in none of five chondrosarcomas, in one of two Ewing's sarcomas, in the bone MFH, not in the chordoma, in three of 13 liposarcomas, in five of 11 MFHs, in six of ten synovial sarcomas, in two of three MPNSTs, and in the leiomyosarcoma (Table 2) . Telomerase activity in liposarcoma, chondrosarcoma, and chordoma was significantly lower than in other malignant tumors (p=0.0046). Of all the malignant tumors (Group II), telomerase activity was detected in 55% of high-grade tumors (26/47) while in only one (liposarcoma) low-grade tumor (1/14) ( Table 3 ) (p=0.002).
Fourteen patients with malignant tumors developed lung metastasis and 47 did not. Telomerase activity was detected in 64% of malignant tumors with lung metastasis (9/14) and in 38% of those without lung metastasis (18/47). Cumulative metastasis-free survival in telomerase-negative patients was significantly higher than in telomerase-positive patients (p=0.045) (Fig. 3) . Cumulative overall survival in telomerase-negative patients was better than in he telomerase-positive patients (p=0.048) (Fig. 4) .
Discussion
Many studies on telomerase activity in carcinomas have reported that it is usually detected in about 81-100% (Meeker and Coffey 1997; Shay and Wright 1996) . As there are few reports on soft tissue tumors (Yoo and Robinson 2000; Yan et al. 1999; Schneider-Stock et al. 2000; Tomoda et al. 2002) and even fewer on bone tumors (Aue et al.1998; Aogi et al. 2000; Sangiorgi et al. 2001) , telomerase activity data on these tumors have not been sufficient to reach any definitive conclusions. Moreover, the frequency of telomerase activity expression in bone and soft tissue tumors differs among the previous reports (17-81%) (Aue et al. 1998; Yoo and Robinson 2000; Yan et al. 1999; Schneider-Stock et al. 2000 , Aogi et al. 2000 Sangiorgi et al. 2001; Tomoda et al. 2002) .
In our study, telomerase activity was detected in 44% of malignant tumors and 10% of benign tumors. Although telomerase activity is generally detected in malignant tumors, our data showed three telomerasepositive benign tumors (two GCTs and one enchondroma). GCT is a benign tumor; however, its activity is locally aggressive, and local recurrence occurs in about 50% after curettage (Unni 1996) . Sangiorgi et al. and Schwartz et al. demonstrated positive telomerase activity of GCTs in their reports (Sangiorgi et al. 2001; Schwartz et al. 1995) . From these studies, telomerase activity could also be detected in locally aggressive benign tumors as well as malignant tumors. On the other hand, Bovee et al. also detected weak telomerase activity in an enchondroma (Bovee et al. 2001) . Enchondroma is sometimes difficult to distinguish accurately from lowgrade chondrosarcoma. Furthermore, enchondroma may develop into a malignant cartilage tumor (Mirra et al. 1985) . These characteristics may explain positive telomerase activity in enchondroma.
In malignant tumors, telomerase activity in highgrade tumors was significantly higher than in lowgrade tumors; however, we could find no statistical significance regarding telomerase activity between primary and recurrent malignant tumors and between malignant tumors with and without lung metastasis. Tomoda et al. reported that when most sarcomas were MFHs and liposarcomas, the frequency of telomerase activity was high in locally recurrent sarcomas and in soft tissue tumors with distant metastases (Tomoda et al. 2002) . This may be partially explained that a lot of recurrent sarcomas or sarcomas with lung metastasis were high-grade sarcomas. Although our study included many malignant bone and soft tissue tumors, Fig. 3 Metastasis-free survival and telomerase activity. Telomerase-positive patients showed a significantly worse clinical course than telomerase-negative patients (p<0.05) Fig. 4 Overall survival and telomerase activity. Telomerasepositive patients showed a significantly worse prognosis than telomerase-negative patients (p<0. 05) we did not find that telomerase activity correlated with local recurrence (primary or recurrent) or lung metastasis (presence or absence). On the other hand, metastasis-free survival was significantly lower and the duration between surgery and recurrence was shorter in telomerase-positive patients. This suggests that tumor development may be influenced by telomerase activity.
Our study also showed that overall survival in telomerase-positive patients was significantly worse than in telomerase-negative patients. There have been many reports on the poor prognosis of telomerase-positive patients with various tumors (Schneider-Stock et al. 1999; Marchetti et al. 1999; Tatsumoto et al. 2000; Verstovsek et al. 2003) . Telomerase activity seems to be one of the significant prognostic parameters.
In high-grade tumors, those without preoperative therapy (Group II) showed a significantly higher incidence of telomerase activity than with preoperative therapy (Group III). Tumor cells were damaged and became inactive after preoperative therapy. Lin et al. reported that telomerase activity was downregulated by radiation and chemotherapy (Lin et al. 2001) . In the Ewing's sarcoma obtained after preoperative therapy (Fig. 1, Lane 4) , the ladder expression was weaker than in telomerase-positive tumors. We did not compare the tumors before and after preoperative therapy; however, radiation and chemotherapy probably suppress the expression of telomerase activity.
According to recent studies, an anticancer effect is obtained by telomerase inhibition, which would shorten the telomeres and downregulate tumor progression (Sharma et al. 1997; Shay and Wright 2002; Saretzki 2003) . Although telomerase inhibition has not yet entered clinical trials, it may become a future treatment strategy against cancer.
In conclusion, telomerase activity correlates with tumor activity in both benign and malignant tumors and with metastasis-free and overall survival. Telomerase activity seems to be a useful parameter in predicting the prognosis of patients with malignant bone and soft tissue tumors, and the regulation of telomerase activity may play an important role in anticancer therapy.
